Nitric oxide inhibits platelet adhesion to platelet-microparticles through reducing integrin αIIbβ3 activation

Nitric oxide (NO) plays a crucial role in regulating platelet activation, particularly in the context of platelet-microparticles (PMPs) that are linked to cardiovascular disease. Elevated levels of PMPs in patients with risk factors for heart disease have been associated with worse clinical outcomes. These microparticles promote thrombosis by enhancing platelet aggregation and binding to the sub-endothelial matrix after vascular injury, effectively acting as both ligands and substrates for platelets.

Nitric oxide, continuously released by the endothelium, is a key regulator of platelet activation, essential for maintaining the balance between hemostasis and thrombosis. However, the extent to which NO influences PMP-induced platelet activation remained unclear. To address this, researchers isolated platelets and PMPs from whole blood and assessed their interactions through adhesion assays and flow cytometry.

They analyzed platelet activation using enzyme-linked immunosorbent assay (ELISA) for ADP and thromboxane-B2, secondary platelet agonists that further promote thrombosis. Additionally, they measured the upregulation of the principal platelet integrin receptor responsible for aggregation, integrin αIIbβ3, using the antibody PAC-1.

The findings revealed that PMP-induced platelet adhesion was associated with and partially dependent on platelet ADP release, thromboxane-B2 production, and αIIbβ3 upregulation. Importantly, NO dose-dependently reduced these events through cGMP-dependent signaling. This study is the first to demonstrate that NO signaling can regulate PMP-induced platelet activation, suggesting a potential avenue for targeting PMP-driven cardiovascular disease processes.